LTC1165126I2 - Žmogaus papilomos viruso vakcinos su išskaidytomis ir vėl surinktomis į virusą panašiomis dalelėmis gamybos būdas - Google Patents

Žmogaus papilomos viruso vakcinos su išskaidytomis ir vėl surinktomis į virusą panašiomis dalelėmis gamybos būdas

Info

Publication number
LTC1165126I2
LTC1165126I2 LTPA2007002C LTPA2007002C LTC1165126I2 LT C1165126 I2 LTC1165126 I2 LT C1165126I2 LT PA2007002 C LTPA2007002 C LT PA2007002C LT PA2007002 C LTPA2007002 C LT PA2007002C LT C1165126 I2 LTC1165126 I2 LT C1165126I2
Authority
LT
Lithuania
Prior art keywords
disrupted
particles
production
human papillomavirus
papillomavirus vaccine
Prior art date
Application number
LTPA2007002C
Other languages
English (en)
Lithuanian (lt)
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26824774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC1165126(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of LTPA2007002I1 publication Critical patent/LTPA2007002I1/lt
Publication of LTC1165126I2 publication Critical patent/LTC1165126I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTPA2007002C 1999-03-26 2007-03-19 Žmogaus papilomos viruso vakcinos su išskaidytomis ir vėl surinktomis į virusą panašiomis dalelėmis gamybos būdas LTC1165126I2 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12652899P 1999-03-26 1999-03-26
US09/524,624 US6245568B1 (en) 1999-03-26 2000-03-13 Human papilloma virus vaccine with disassembled and reassembled virus-like particles
PCT/US2000/007595 WO2000057906A1 (en) 1999-03-26 2000-03-22 Human papillomavirus vaccine with disassembled and reassembled virus-like particles

Publications (2)

Publication Number Publication Date
LTPA2007002I1 LTPA2007002I1 (lt) 2020-03-25
LTC1165126I2 true LTC1165126I2 (lt) 2020-04-27

Family

ID=26824774

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2007002C LTC1165126I2 (lt) 1999-03-26 2007-03-19 Žmogaus papilomos viruso vakcinos su išskaidytomis ir vėl surinktomis į virusą panašiomis dalelėmis gamybos būdas

Country Status (19)

Country Link
US (2) US6245568B1 (enExample)
EP (1) EP1165126B1 (enExample)
JP (1) JP4594534B2 (enExample)
KR (1) KR20020013516A (enExample)
AR (1) AR023166A1 (enExample)
AT (1) ATE339222T1 (enExample)
AU (1) AU778937B2 (enExample)
CA (1) CA2368391C (enExample)
CY (4) CY1105779T1 (enExample)
DE (4) DE122007000034I1 (enExample)
DK (1) DK1165126T3 (enExample)
ES (1) ES2270822T3 (enExample)
FR (1) FR07C0026I2 (enExample)
LT (1) LTC1165126I2 (enExample)
LU (3) LU91328I2 (enExample)
NL (3) NL300270I1 (enExample)
PT (1) PT1165126E (enExample)
SI (1) SI1165126T1 (enExample)
WO (1) WO2000057906A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
EP1250593B1 (en) * 1999-12-09 2009-03-25 Medimmune, Inc. IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs)
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003068804A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10237639A1 (de) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CA2503871C (en) 2002-11-01 2012-12-11 Glaxosmithkline Biologicals S.A. An immunogenic composition for generating an immune response against polio virus
PT1572233E (pt) 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US20080131928A1 (en) * 2004-07-01 2008-06-05 Hiroshi Handa Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions
EP1841474A2 (en) * 2005-01-25 2007-10-10 Wyeth Research Ireland Limited Method for diafiltration
JP2009501520A (ja) * 2005-07-14 2009-01-22 メイヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パラミクソウイルス科ウイルス調製物
WO2007020871A1 (ja) * 2005-08-12 2007-02-22 Astellas Pharma Inc. デプシペプチド含有注射液
WO2007027076A1 (es) * 2005-09-01 2007-03-08 Nuno Ayala Jose Luis Formula estabilizadora de vacunas con antígenos vivos para su uso en sistemas de vacunación masiva
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8962262B2 (en) * 2006-05-11 2015-02-24 Arbor Vita Corporation Method of protein extraction from cells
US9207240B2 (en) * 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
JP5313231B2 (ja) * 2008-03-31 2013-10-09 森永乳業株式会社 耐熱性を付与する薬剤及び組成物
ES2660762T3 (es) * 2009-09-03 2018-03-26 Becton, Dickinson And Company Métodos y composiciones para lisis química directa
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN104203270A (zh) 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
US20200010850A1 (en) 2017-02-17 2020-01-09 The USA, as represeented by the Secretary, Dept. of Health and Human Services Efficient cell free production of papillomavirus gene transfer vectors
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110987571A (zh) * 2019-12-31 2020-04-10 广州金域医学检验中心有限公司 一种单克隆多聚体m蛋白解聚方法
CN111812313B (zh) * 2020-06-22 2021-10-08 北京生物制品研究所有限责任公司 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法
TW202334423A (zh) * 2021-12-15 2023-09-01 美商旗艦先鋒創新公司 表面經修飾之病毒顆粒及模組化之病毒顆粒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515056A (ja) * 1997-02-06 2002-05-21 メルク エンド カンパニー インコーポレーテッド ワクチン用チメロサールフリー保存剤
WO1998044944A2 (en) 1997-04-08 1998-10-15 Merck & Co., Inc. Stabilized human papillomavirus formulations
AU755679B2 (en) 1997-07-03 2002-12-19 Medimmune, Llc Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy

Also Published As

Publication number Publication date
NL300268I1 (nl) 2007-05-01
LU91328I2 (fr) 2007-05-14
SI1165126T1 (sl) 2006-12-31
WO2000057906A1 (en) 2000-10-05
CY2007009I2 (el) 2010-07-28
EP1165126A1 (en) 2002-01-02
FR07C0026I2 (fr) 2012-08-03
CY2007010I1 (el) 2009-11-04
CY1105779T1 (el) 2010-07-28
CY2007009I1 (el) 2010-07-28
DE60030698D1 (de) 2006-10-26
NL300269I2 (nl) 2008-07-01
FR07C0026I1 (enExample) 2007-04-27
NL300269I1 (nl) 2007-05-01
LU91326I2 (fr) 2007-05-14
CY2007008I1 (el) 2009-11-04
NL300270I1 (nl) 2007-05-01
CA2368391A1 (en) 2000-10-05
LTPA2007002I1 (lt) 2020-03-25
EP1165126B1 (en) 2006-09-13
LU91328I9 (enExample) 2019-03-01
US6245568B1 (en) 2001-06-12
US20010021385A1 (en) 2001-09-13
AU3909300A (en) 2000-10-16
DE122007000032I1 (de) 2007-08-09
LU91327I2 (fr) 2007-05-14
JP2002540167A (ja) 2002-11-26
ES2270822T3 (es) 2007-04-16
ATE339222T1 (de) 2006-10-15
LU91326I9 (enExample) 2018-12-31
DE60030698T2 (de) 2007-07-19
DE122007000034I1 (de) 2007-08-09
CY2007010I2 (el) 2009-11-04
AU778937B2 (en) 2004-12-23
AR023166A1 (es) 2002-09-04
CA2368391C (en) 2011-06-07
LU91327I9 (enExample) 2019-03-01
DK1165126T3 (da) 2007-01-08
DE122007000033I1 (de) 2007-08-09
PT1165126E (pt) 2006-12-29
KR20020013516A (ko) 2002-02-20
JP4594534B2 (ja) 2010-12-08
CY2007008I2 (el) 2009-11-04

Similar Documents

Publication Publication Date Title
LTPA2007002I1 (lt) Žmogaus papilomos viruso vakcinos su išskaidytomis ir vėl surinktomis į virusą panašiomis dalelėmis gamybos būdas
AP2004003136A0 (en) Virus-like particles of human papillomavirus
NO2012016I1 (no) Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler
AU2003235707A8 (en) Immunogenic preparations and vaccines on the basis of mrna
EP1793850A4 (en) ANTIBODIES TO THE METHOD AND METHOD FOR THE PRODUCTION OF VACCINES AGAINST THE RESPIRATORY SYNCYTIAL VIRUS
AU2003298998A1 (en) Oriented nanostructures and methods of preparing
TWI349557B (en) Use of hpv 16 and hpv 18 vlps for vaccine preparation
DE60040879D1 (de) Impfstoff gegen Hbv und Hpv
AU4971500A (en) Production of novel newcastle disease virus strains from cdnas and improved liveattenuated newcastle disease vaccines
AU2001241918A1 (en) Methods of enhancing activity of vaccines and vaccine compositions
AU2003271021A1 (en) Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof
AU2001269640A1 (en) Vaccine against the influenza virus and method for producing said virus vaccine
AU2003290012A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
AU2003278175A1 (en) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
GB0622256D0 (en) Pharmaceutics of traditional chinese medicine of treating aids and preparation method thereof
EP1576966A4 (en) PROCESS FOR PREPARING A VACCINE AND ANTITUMOR VACCINES
AU2003228816A8 (en) Production of papillomavirus vaccines in plants
AU2003287216A1 (en) Gb virus c and methods of treating viral infections
FI20020375A7 (fi) Menetelmä viruksen kaltaisten partikkeleiden (VKP) tuottamiseksi, plasmidikonstrukti sekä menetelmän käytöt
AUPR020900A0 (en) Vaccines and methods of vaccination
HK1072378A (en) Virus-like particles of human papillomavirus
AUPR042100A0 (en) Vaccines and methods of vaccination
GB0313844D0 (en) Materials and methods relating to the treatment of viral diseases
HK1102911A (en) Lipid-extracted therapeutic vaccine and method of use
AUPQ692200A0 (en) Vaccines and methods for the treatment of human melanoma